Search results for: Novartis
Filter search results
After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
1 November 2021
…Report was commissioned and funded by Novartis Pharmaceuticals. Novartis Pharmaceuticals were consulted throughout the development of the report and this post and had editorial input to the final draft. Novartis…
The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
18 July 2023
…has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians. Key…
The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
1 April 2014
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis…
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…Managed Care & Specialty Pharmacy, 29(3), pp.229–235. 10.18553/jmcp.2023.29.3.229. MedPAC, 2023. Data book [online] July 2023. Available at: https://www.medpac.gov/wp-content/uploads/2023/07/July2023_ [Accessed 30 September 2023] Taylor, P., 2023. Novartis hits back at Entresto…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
…research is needed to explore how policymakers can apply these ideas in practice. This report was commissioned by Novartis Gene Therapies. The programme of research also included a debate on…
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
…place. Acknowledgement: This report was commissioned by Novartis Gene Therapies. Citation Firth I., Schirrmacher H., Hampson G., Towse A. Key considerations for early access schemes for one-time therapies., London: Office…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…on an OHE study funded by Novartis Molecular Diagnostics. Implications of Co-Dependent Technologies in Medicine from Office of Health Economics Access to OHE publications is available free of charge…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
…in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis[1]. A…
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
…by a consortium of five pharmaceutical companies: Amgen, GSK, Lilly, Novartis, and Sanofi. References: Towse, A., Garau, M., Mohr, P. and Messner, D.A., 2015. Futurescapes: expectations in Europe for relative…